Chevron envisions Moon site
Chevron has signaled in zoning documents that it intends to build a regional headquarters to oversee its Marcellus shale gas drilling operations on a 61-acre site it has acquired in Moon despite maintaining that it won't make a decision until next year.
In an application for a rezoning of the site, which the company filed in September, it said the proposed campus that Chevron anticipates to be constructed there would be the regional headquarters for Chevron's Appalachian-Michigan Business Unit, which manages the company's natural gas production assets in Pennsylvania, West Virginia and Michigan.
The Moon Planning Commission has approved the rezoning from highway commercial to business park. The change still must be approved by the township supervisors, who plan to hold a public hearing on Nov. 6.
The application outlines plans for a headquarters campus that would include 414,000-square-foot office building, a 123,000-square-foot commons building, a 44,250-square-foot technical center, a garage with 1,200 parking stalls and a 23,000-square-foot freestanding central plant facility.
Chevron said in its zoning application that it foresees the campus including, among other things, conventional business office space, a visitors welcome center, a gym and an employee dining facility.
Chevron spokesman Trip Oliver said on Thursday that the company still hasn't decided whether the site will be its regional headquarters. He said a decision won't be made until the second quarter of 2014.
“Chevron filed a request with Moon officials to have the site rezoned to accommodate a potential headquarters campus there,” he said. “The change would permit Chevron if it decides to place a regional headquarters there, to obtain the necessary permits for construction.”
Sam Spatter is a staff writer for Trib Total Media. He can be reached at 412-320-7843 or firstname.lastname@example.org.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Wolf reverses Corbett, says deal between Highmark, UPMC doesn’t limit continuity of care to very ill
- Americans see improved job market but a vulnerable economy, Pew poll finds
- Big banks’ levels of capital strong, Federal Reserve finds
- AbbVie to buy leukemia drugmaker Pharmacyclics for $21 billion
- IPO might test Etsy’s approach to commerce
- Researchers: U.S. lacks proving ground for nuclear energy innovations
- Race toward bigger phones eases
- Mylan closes $5.3B tax-lowering deal with Abbott Labs
- Worker productivity falls faster than estimated; labor costs rise
- Stocks snap losing streak as ECB reveals stimulus start date
- Shift in what powers the grid raises concerns about fuel diversity